Equities research analysts expect Icon Plc (NASDAQ:ICLR) to report $622.99 million in sales for the current quarter, according to Zacks. Six analysts have issued estimates for Icon’s earnings. The lowest sales estimate is $607.77 million and the highest is $638.40 million. Icon posted sales of $431.95 million during the same quarter last year, which would indicate a positive year over year growth rate of 44.2%. The business is expected to announce its next earnings results on Thursday, April 26th.
According to Zacks, analysts expect that Icon will report full year sales of $622.99 million for the current year, with estimates ranging from $2.57 billion to $2.61 billion. For the next fiscal year, analysts expect that the firm will post sales of $2.76 billion per share, with estimates ranging from $2.74 billion to $2.81 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Icon.
Icon (NASDAQ:ICLR) last released its quarterly earnings results on Thursday, February 15th. The medical research company reported $1.43 earnings per share for the quarter, topping analysts’ consensus estimates of $1.41 by $0.02. The company had revenue of $455.10 million during the quarter, compared to analysts’ expectations of $455.66 million. Icon had a return on equity of 27.55% and a net margin of 16.01%. Icon’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.33 EPS.
A number of large investors have recently bought and sold shares of the business. WCM Investment Management CA increased its stake in Icon by 5.8% during the 4th quarter. WCM Investment Management CA now owns 4,281,211 shares of the medical research company’s stock worth $480,138,000 after buying an additional 233,990 shares in the last quarter. Alliancebernstein L.P. increased its stake in Icon by 1.0% during the 4th quarter. Alliancebernstein L.P. now owns 2,560,367 shares of the medical research company’s stock worth $287,145,000 after buying an additional 24,571 shares in the last quarter. Clearbridge Investments LLC increased its stake in Icon by 1.0% during the 4th quarter. Clearbridge Investments LLC now owns 1,897,429 shares of the medical research company’s stock worth $212,797,000 after buying an additional 18,041 shares in the last quarter. Renaissance Technologies LLC increased its stake in Icon by 37.5% during the 4th quarter. Renaissance Technologies LLC now owns 1,817,307 shares of the medical research company’s stock worth $203,811,000 after buying an additional 495,247 shares in the last quarter. Finally, Boston Partners increased its stake in Icon by 0.5% during the 4th quarter. Boston Partners now owns 1,111,725 shares of the medical research company’s stock worth $124,680,000 after buying an additional 5,314 shares in the last quarter. Institutional investors own 90.50% of the company’s stock.
Icon (ICLR) opened at $123.90 on Tuesday. The firm has a market capitalization of $6,700.00, a PE ratio of 23.47, a P/E/G ratio of 1.73 and a beta of 0.45. Icon has a fifty-two week low of $76.46 and a fifty-two week high of $124.65. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.29.
WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/03/13/zacks-brokerages-anticipate-icon-plc-iclr-will-post-quarterly-sales-of-622-99-million.html.
Icon Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.